Severe Atopic Dermatitis

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients with moderate to severe atopic dermatitis, the company announced in a press release.

Patients with moderate to severe atopic dermatitis treated with amlitelimab showed both clinical and biomarker improvements, including in patients who withdrew from treatment, according to phase 2b trial results.

LEO Pharma presented full results from its long-term trial of Adbry for atopic dermatitis at the Fall Clinical Dermatology Conference, according to a company press release.

New interim, long-term results showed that nemolizumab improved signs and symptoms of atopic dermatitis including sleep, itch and quality of life, according to a presentation at the European Academy of Dermatology and Venereology Congress.

Adbry 300 mg/2 mL single-dose autoinjector is now available for the treatment of adults with moderate to severe atopic dermatitis in the U.S., LEO Pharma announced in a press release.

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.